Mark Biagi

Dr. Mark Biagi


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
NRNicholas Rebold
Nicholas Rebold
TMTaylor Morrisette
Taylor Morrisette
ALAbdalhamid M Lagnf
Abdalhamid M Lagnf
SASara Alosaimy
Sara Alosaimy
DHDana Holger
Dana Holger
MRMichael J. Rybak
Michael J. Rybak
A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67%) patients. Two patients experienced adverse effects.

16 March 2019 in Antibiotics
Verified
Journal Article
Open access
PDF file
MBMark Biagi
Mark Biagi
DBDavid A Butler
David A Butler
XTXing Tan
Xing Tan
SQSamah Qasmieh
Samah Qasmieh
EWEric Wenzler
Eric Wenzler
Despite advancements in therapy, pneumonia remains the leading cause of death due to infectious diseases. Novel treatment strategies are desperately needed to optimize the antimicrobial therapy of patients suffering from this disease. One such strategy that has recently garnered significant attention is the use of inhaled antibiotics to rapidly achieve therapeutic concentrations directly at the site of infection. In particular, there is significant interest in the role of inhaled polymyxins for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia, due to their retained activity against multi-drug resistant Gram-negative pathogens, including Acinetobacter baumannii and Pseudomonas aeruginosa. This review will provide a comprehensive overview of the pharmacokinetic/pharmacodynamic profile, clinical outcomes, safety, and potential role of inhaled polymyxins in clinical practice.

26 February 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
KCKaylee E Caniff
Kaylee E Caniff
NRNicholas Rebold
Nicholas Rebold
XXXhilda Xhemali
Xhilda Xhemali
NTNikki Tran
Nikki Tran
TETaryn Ashley Eubank
Taryn Ashley Eubank
MRMichael J. Rybak
Michael J. Rybak
Background: Multidrug-resistant (MDR) gram-negative infections are a substantial threat to patients and public health. Imipenem-cilastatin-relebactam (IMI/REL) is a β-lactam/β-lactamase inhibitor with expanded activity against MDR Pseudomonas aeruginosa and carbapenem-resistant Enterobacterales. This study aims to describe the patient characteristics, prescribing patterns, and clinical outcomes associated with IMI/REL. Methods: This was a retrospective, multicenter, observational study of patients ≥18 years old who received IMI/REL for ≥48 hours for a suspected or confirmed gram-negative infection. The primary outcome was clinical success, defined as improvement or resolution of infection-related signs or symptoms while receiving IMI/REL and the absence of 30-day microbiologic failure. Multivariable logistic regression analysis was performed to identify independent predictors of clinical success. Results: The study included 151 patients from 24 US medical centers. IMI/REL was predominantly prescribed for lower respiratory tract infections, accounting for 52.3% of cases. Most patients were infected with a carbapenem-nonsusceptible pathogen (85.4%); P aeruginosa was frequently targeted (72.2%). Clinical success was achieved in 70.2% of patients. Heart failure, receipt of antibiotics within the past 90 days, intensive care unit admission at time of index culture collection, and isolation of difficult-to-treat resistant P aeruginosa were independently associated with a reduced odds of clinical success. Adverse events were reported in 6.0% of patients, leading to discontinuation of IMI/REL in 3 instances. Conclusions: This study provides a comprehensive analysis of the real-world effectiveness and safety of IMI/REL. Comparative studies and investigations of specific subgroups will further enhance our understanding of IMI/REL in treating MDR infections.

5 September 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
MPMichael Pierce
Michael Pierce
WSWendy Slipke
Wendy Slipke
MBMark Biagi
Mark Biagi
Bordetella bronchiseptica infections may be overlooked by clinicians due to the uncommon encounter of this pathogen in humans and common isolation of co-pathogens. However, the isolation of B. bronchiseptica in immunocompromised individuals may represent a true infection. We report our experience with the fatal case of a stem cell transplant recipient, co-infected with SARS-CoV-2 and B. bronchiseptica, who was considered fully vaccinated (two doses) at the time of her case in spring 2021. Future studies are needed to evaluate the incidence of bacterial co-infections in immunosuppressed individuals with SARS-CoV-2 and clinicians should remain cognizant of the potential pathogenic role of uncommon pathogens isolated in these individuals.

29 October 2020 in International Journal of STD & AIDS
Verified
Journal Article
Closed access
PDF file
MBMark Biagi
Mark Biagi
WSWendy Slipke
Wendy Slipke
ASAlexa Smalley
Alexa Smalley
GTGeoffrey Tsaras
Geoffrey Tsaras
Metronidazole desensitization is recommended in patients with trichomoniasis and history of an allergic reaction to metronidazole due to presumed cross reactivity with tinidazole and lack of reliably safe and effective alternative therapies. We report our experiences in a patient with persistent trichomoniasis who failed to complete metronidazole desensitization due to a burning sensation over her whole body and pruritus but was later successfully desensitized to tinidazole without experiencing any adverse effects.

30 September 2019 in Pharmacy Practice
Verified
Journal Article
Open access
PDF file
TCThomas D. Chiampas
Thomas D. Chiampas
MBMark Biagi
Mark Biagi
MBMelissa E Badowski
Melissa E Badowski
Pharmacy Practice is a free full-text journal with a scope on the practice of pharmacy. Pharmacy Practice covers pharmaceutical care, social pharmacy, pharmacy education, process and outcome research, health promotion and education, health informatics, pharmacoepidemiology